B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $314

Benzinga · 10/14 17:50
B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $307 to $314.